Tobacco.org

Bayer starts clinical Phase I study with personalized vaccine from tobacco plants  

The transfer into clinical development of a patient-specific vaccine represents a milestone for Bayer Innovation GmbH. Following approval of the Phase I study by the FDA (Food & Drug Administration) in the United States, the vaccine is now being tested in human subjects. This is the first time that proteins obtained from tobacco plants using magnICON® technology undergo clinical testing. The patient-specific vaccines produced in the pilot plant operated by the Bayer-subsidiary Icon Genetics in Halle, Germany, are intended for the treatment of non-Hodgkin's lymphoma (NHL), a type of cancer affecting lymphocytes. The objective of the therapy is to activate the patient's immune system, enabling the malignant cells to be targeted and destroyed by the body's own defense system.

"This personalized vaccine is being developed with the aim of keeping patients who have responded well to chemotherapy in complete remission," explains Dr. Detlef Wollweber, head of Bayer Innovation GmbH. "In other words, it should prevent a recurrence of the tumor. The initiation of this clinical trial also demonstrates that our magnICON® technology is suitable for manufacturing proteins for potential pharmaceutical applications."

Jump to full article »